Pharmaceutical licensing in Japan and overseas
First written in FY2017-Q1. 18 of 35 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-11-09.
No other company in this theme has enough history to compare yet.
- FY2026DroppedAnnual report
「As the agreement between our company and Spruce Biosciences for the exclusive development and sales rights in Japan for tildacerfont, a treatment for congenital adrenal hyperplasia, ended effective 31 March 2026, it has been removed from the list.」
The exclusive development and sales agreement for tildacerfont in Japan ended, and it was removed from the list of material agreements. - FY2026AdvancedAnnual report
「The Group entered into a strategic licensing and co-development agreement with Numab Therapeutics AG (hereinafter, Numab) for the novel multispecific antibody drug NM81 for inflammatory bowel disease. The Group began domestic sales of Ekterly, a plasma kallikrein inhibitor for acute attacks of hereditary angioedema, for which KalVista obtained marketing approval and whose generic name is sebetralstat. Dong-Wha Pharm. Co.,Ltd., our licensee in South Korea for Eklira, launched the product in South Korea.」
In addition to newly executing a licensing and co-development agreement for NM81 in Japan and Asia, the commercialisation territories and stages of the in-licensed and out-licensed products advanced through the domestic launch of Ekterly, the South Korean launch of Eklira, and the marketing approval of Jublia in Germany. - FY2026-H1AdvancedAnnual report
「Entered into a licensing agreement for the commercialisation in Japan of sebetralstat, for which KalVista is seeking marketing approval as a treatment for hereditary angioedema. Under the agreement, the Group acquired the exclusive sales rights for sebetralstat in Japan. Entered into a licensing agreement for gMSC1. Under the agreement, the Group acquired co-development rights and exclusive sales rights in the orthopaedic field in Japan. Entered into a licensing agreement for navenibart covering development and commercialisation in Japan. Under the agreement, the Group acquired the exclusive development and sales rights for navenibart in Japan.」
Newly acquired sales rights in Japan for sebetralstat, co-development rights for gMSC1, and development and sales rights for navenibart. In addition, SANYO CHEMICAL INDUSTRIES,LTD. obtained marketing approval for the silk-elastin wound sheet, Eklira reached the marketing approval stage in South Korea, and Jublia reached the marketing approval stage in Germany. - FY2025-H1AdvancedAnnual report
「Transfer of intellectual property relating to a novel multispecific antibody, milestone income rights linked to progress in development in Japan and Asia and achievement of sales targets, royalty income rights linked to sales in Asia, and an option to negotiate a sales partnership in Japan」
For NM26, acquired the transfer of intellectual property to シーラグ社, milestone and royalty income rights linked to J&J's development in Japan and Asia, and an option to negotiate a sales partnership in Japan. A total of US$86 million has been received as an upfront payment. In addition, licensed the exclusive sales rights in Japan for a silk-elastin wound sheet from SANYO CHEMICAL INDUSTRIES,LTD., expanding the product portfolio. - FY2024-Q3RestatedAnnual report
「There were no decisions to enter into or executions of material management-related contracts or similar agreements during the third quarter.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2024-Q2AdvancedAnnual report
「During the consolidated six-month period ended September 2023, we launched a twist bottle in June 2023 as a new container for Eklira, a treatment for primary axillary hyperhidrosis, allowing the drug to be applied directly to the axilla. In August 2023, we launched NexoBrid, a debridement agent. NexoBrid is a topical formulation indicated for the removal of necrotic tissue in deep partial-thickness or full-thickness burns, providing a new treatment option, and we are conducting information activities primarily among burn specialists to help improve patients' quality of life. In September 2023, Dong-Wha, our partner in South Korea, submitted an application for marketing approval in South Korea for Eklira, a treatment for primary axillary hyperhidrosis. We have granted Dong-Wha the exclusive development and sales rights for this product in South Korea.」
Regarding the existing licensing operations, NexoBrid reached its domestic launch, and a marketing approval application was submitted in South Korea for Eklira. - FY2024-Q1AdvancedAnnual report
「Our company ドンファ社 South Korea Exclusive development and sales rights for Eklira in South Korea From June 2023 until the later of the patent expiry date or the date 10 years after the start of sales (automatically extended every 2 years thereafter)」
A new agreement was executed to license the exclusive development and sales rights for Eklira in South Korea to Dong-Wha, expanding the overseas licensing operations to South Korea. - FY2023-Q3DroppedAnnual report
「The contracts that ended during the consolidated third quarter are as follows. Sales agreement (out-licensing): our company; 台田薬品社; Taiwan; exclusive sales rights for Jublia in Taiwan; from 2017」
The exclusive sales agreement with 台田薬品社 for Jublia in Taiwan ended during the consolidated third quarter. - FY2023-Q2RestatedAnnual report
「During the second-quarter consolidated accounting period, there were no decisions to enter into, or executions of, material management contracts or other agreements.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2023-Q1ReframedAnnual report
「As the contractual position was transferred from Brickell Biotech to Botanix SB in connection with the transfer of the business, effective 3 May 2022, the counterparty's name has been changed.」
Under the agreement concerning the exclusive development rights and other rights for BBI-4000 in Japan and Asia, the contractual position was transferred from Brickell Biotech to Botanix SB in connection with the transfer of the business, and the name of the counterparty was changed. - FY2022RestatedAnnual report
「During the fiscal year, we entered into an exclusive licensing and supply agreement with Almirall for Europe.」
The annual report also confirms the execution of an exclusive licensing agreement with Almirall for Jublia in Europe. No material additional progress beyond the European expansion already reported in the previous quarter has been indicated. - FY2022-Q2AdvancedAnnual report
「アルミラル社 Spain Exclusive development and sales rights for Jublia in Europe From July 2021 until the later of the patent expiry date, the design right expiry date, or the date 10 years after the start of sales in any European country」
A new agreement was executed to license the exclusive development and sales rights for Jublia in Europe to Almirall, expanding the overseas licensing operations to Europe. - FY2022-Q1RestatedAnnual report
「There were no decisions on or execution of material contracts or other agreements during the first quarter of the consolidated fiscal year.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2021AdvancedAnnual report
「Exclusive development rights and manufacturing and sales rights in Japan and Asia for a novel multispecific antibody drug for atopic dermatitis From January 2021 until the later of the patent expiry date or the date 20 years after execution of the agreement」
Entered into a licensing and co-development agreement with Numab Therapeutics for Japan and Asia. In addition, began a co-promotion agreement with Mochida Pharmaceutical for teriparatide BS. Some agreements with GeneTechno Science, 北京泰徳製薬, and ボシュ・ヘルス社 have ended, resulting in both additions to and terminations of licensing arrangements. - FY2021-Q2RestatedAnnual report
「During the second-quarter consolidated accounting period, there were no decisions to enter into, or executions of, material management contracts or other agreements.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2021-Q1RestatedAnnual report
「There were no decisions on or execution of material contracts or other agreements during the first quarter of the consolidated fiscal year.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2020-Q3RestatedAnnual report
「There were no decisions to enter into or executions of material management-related contracts or similar agreements during the third quarter.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2020-Q1RestatedAnnual report
「There were no decisions on or execution of material contracts or other agreements during the first quarter of the consolidated fiscal year.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2019AdvancedAnnual report
「天津泰普滬亜医薬知識産権流転儲備中心社 China Exclusive development and sales rights for Jublia in China (excluding Hong Kong and Macau) From February 2019 until the date 10 years after the start of sales (automatically extended every 2 years thereafter)」
The territory to which Jublia was licensed expanded to mainland China, following Hong Kong and Macau. In addition, the exclusive development and sales rights in Japan for Lenabasum from コーバス社 and KAR from アーバー社 were licensed in January and February 2019, respectively. - FY2019-Q3AdvancedAnnual report
「メインライフ社 China Exclusive sales rights for Jublia in Hong Kong and Macau From October 2018 until the date 10 years after the start of sales (automatically extended every 2 years thereafter)」
A new agreement was executed to license the exclusive sales rights for Jublia in Hong Kong and Macau to メインライフ社 in China. In addition, the agreement with ボシュ・ヘルス社 was changed to cover exclusive sales rights and other rights in all countries except Japan, China, Taiwan, and South Korea, expanding and reorganising the overseas licensing operations. - FY2019-Q2RestatedAnnual report
「During the second-quarter consolidated accounting period, there were no decisions to enter into, or executions of, material management contracts or other agreements.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2019-Q1RestatedAnnual report
「There were no decisions on or execution of material contracts or other agreements during the first quarter of the consolidated fiscal year.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2018AdvancedAnnual report
「Exclusive development and exclusive sales rights in the US, Canada, and Western and Eastern Europe for the topical KP-470 formulation for psoriasis and other dermatological diseases and rheumatic diseases」
The licensing of the exclusive development and sales rights for the topical KP-470 formulation to Variant began in February 2018, expanding the overseas licensing operations to North America and Europe. - FY2018-Q3AdvancedAnnual report
「台田薬品股份有限公司 Taiwan Exclusive sales rights for Jublia in Taiwan From November 2017 until the date 10 years after the start of sales (automatically extended every 2 years thereafter)」
A new sales agreement was executed to license the exclusive sales rights for Jublia in Taiwan to 台田薬品股份有限公司. The contract is for an initial term of 10 years after the start of sales and is automatically extended every 2 years thereafter, expanding the overseas licensing operations to Taiwan. - FY2018-Q2RestatedAnnual report
「During the second-quarter consolidated accounting period, there were no decisions to enter into, or executions of, material management contracts or other agreements.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. - FY2018-Q1RestatedAnnual report
「There were no decisions on or execution of material contracts or other agreements during the first quarter of the consolidated fiscal year.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed, and no change to or expansion of the existing operations has been reported. - FY2017AdvancedAnnual report
「For the burn eschar debridement agent KMW-1 licensed from MediWounds, a clinical trial consultation was held in preparation for starting clinical trials.」
The existing NexoBrid licensing project has progressed to the stage of holding a clinical trial consultation in preparation for starting clinical trials. - FY2017-Q3RestatedAnnual report
「There were no decisions to enter into or executions of material management-related contracts or similar agreements during the third quarter.」
It has been stated that no new material agreements relating to licensing in Japan or overseas were decided on or executed. No new developments indicating a change to or expansion of the existing licensing operations have been reported. - FY2017-Q2AdvancedAnnual report
「Co-promotion of Desalex in Japan」
Entered into a co-promotion agreement with KYORIN Pharmaceutical Co.,Ltd. for Desalex in Japan in July 2016. The contract runs until the later of the end of the reexamination period or 10 years after the start of sales, and an additional partnership structure was established for product development in Japan. - FY2017-Q1First statedAnnual report
「Exclusive development and sales rights in Japan for NexoBrid, a debridement agent for burn eschar」
Licensed the exclusive development and sales rights in Japan from MediWounds. The contract runs for 10 years from April 2016 or from the start of sales, and in South Korea the exclusive sales rights for Jublia have been licensed to 東亞ＳＴ社.